CU23740A1 - Método de obtención de una formulación de antígenos del virus de la hepatitis b - Google Patents

Método de obtención de una formulación de antígenos del virus de la hepatitis b

Info

Publication number
CU23740A1
CU23740A1 CU20090164A CU20090164A CU23740A1 CU 23740 A1 CU23740 A1 CU 23740A1 CU 20090164 A CU20090164 A CU 20090164A CU 20090164 A CU20090164 A CU 20090164A CU 23740 A1 CU23740 A1 CU 23740A1
Authority
CU
Cuba
Prior art keywords
formulation
antigens
hbv
cells
stimulation
Prior art date
Application number
CU20090164A
Other languages
English (en)
Inventor
Perez Heidy Trujillo
Inguanzo Dunia Hernandez
Blanco Sonia Gonzalez
Gomez Raimundo Ubieta
Mato Yadira Lobaina
Rubido Julio Cesar Aguilar
Almeida Freya De Los Milagros Freyre
Nieto Gerardo Enrique Guillen
Gonzalez Verena Lucila Muzio
Arias Eduardo Penton
Martinez Luis Saturnino Herrera
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20090164A priority Critical patent/CU23740A1/es
Priority to CA2775794A priority patent/CA2775794A1/en
Priority to CN2010800489910A priority patent/CN102665687A/zh
Priority to EP10770699A priority patent/EP2484343A1/en
Priority to JP2012531233A priority patent/JP2013505971A/ja
Priority to KR1020127008797A priority patent/KR20120080598A/ko
Priority to US13/498,842 priority patent/US20120308615A1/en
Priority to BR112012007180A priority patent/BR112012007180A2/pt
Priority to PCT/CU2010/000003 priority patent/WO2011038701A1/es
Priority to AU2010302740A priority patent/AU2010302740A1/en
Priority to RU2012117233/10A priority patent/RU2012117233A/ru
Publication of CU23740A1 publication Critical patent/CU23740A1/es
Priority to ZA2012/02768A priority patent/ZA201202768B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con el campo de la inmunización terapéutica, específicamente con el empleo de una nueva formulación de antígenos del virus de la Hepatitis B (VHB) para la estimulación celular. La formulación está formada por precipitados en suspensión de los antígenos de la superficie (HBsAg) y de la nucleocápsida (HBcAg) del VHB. La formulación contiene a dichos antígenos como precipitados en suspensión de partículas de tallas inferiores a 500 nm y superiores a 500nm, en una mezcla donde la proporción entre las partículas de las tallas mencionadas está entre 50%-50% y 80%-20%, respectivamente. La selección de un rango de tallas de partículas permite que los niveles de estimulación de varios tipos celulares sea el máximo. Adicionalmente, se describe3 un método de estimulación celular con dicha formulación, y la posterior inmunización pasiva de pacientes con Hepatitis B crónica, basado en la máxima estimulación in vivo o in vitro de células heterólogas o autólogas (células dendríticas, células B y macrófagos). Las células estimuladas con esta formulación se transfieren a pacientes infectados crónicamente con el VHB.
CU20090164A 2009-09-29 2009-09-29 Método de obtención de una formulación de antígenos del virus de la hepatitis b CU23740A1 (es)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CU20090164A CU23740A1 (es) 2009-09-29 2009-09-29 Método de obtención de una formulación de antígenos del virus de la hepatitis b
KR1020127008797A KR20120080598A (ko) 2009-09-29 2010-09-28 치료적 면역화반응이 따르는 세포 자극용 비형 간염 바이러스 항원의 제형
CN2010800489910A CN102665687A (zh) 2009-09-29 2010-09-28 用于细胞刺激随后进行治疗性免疫的乙肝病毒抗原制剂
EP10770699A EP2484343A1 (en) 2009-09-29 2010-09-28 Hepatitis b virus antigen formulation for cell stimulation followed by therapeutic immunization
JP2012531233A JP2013505971A (ja) 2009-09-29 2010-09-28 治療上の免疫化後の細胞性刺激のためのｂ型肝炎ウイルス抗原製剤
CA2775794A CA2775794A1 (en) 2009-09-29 2010-09-28 Formulation of hepatitis b virus antigens for cellular stimulation followed by therapeutic immunization
US13/498,842 US20120308615A1 (en) 2009-09-29 2010-09-28 Formulation of hepatitis b virus antigens for cellular stimulation followed by therapeutic immunization
BR112012007180A BR112012007180A2 (pt) 2009-09-29 2010-09-28 formulação dos antígenos da superfície e do nucleocapsídio do vírus da hepatite b, métodos de obtenção de uma formulação dos antígenos da superfície e do nucleocapsídio do vírus da hepatite b, de estimulação de células para a imunoterapia passiva e de imunização passiva de pacientes com hepatite b crônica e uso de uma formulação composta por precipitados em suspensão dos antígenos da superfície e do nucleocapsídio do vírus da hepatite b
PCT/CU2010/000003 WO2011038701A1 (es) 2009-09-29 2010-09-28 Formulación de antigenos del virus de la hepatitis b para la estimulación celular seguida de la inmunización terapéutica
AU2010302740A AU2010302740A1 (en) 2009-09-29 2010-09-28 Hepatitis B virus antigen formulation for cell stimulation followed by therapeutic immunization
RU2012117233/10A RU2012117233A (ru) 2009-09-29 2010-09-28 Состав антигенов вируса гепатита в для клеточной стимуляции с последующей терапевтической иммунизацией
ZA2012/02768A ZA201202768B (en) 2009-09-29 2012-04-16 Hepatitis b virus antigen formulation for cell stimulation followed by therapeutic immunization

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20090164A CU23740A1 (es) 2009-09-29 2009-09-29 Método de obtención de una formulación de antígenos del virus de la hepatitis b

Publications (1)

Publication Number Publication Date
CU23740A1 true CU23740A1 (es) 2011-12-28

Family

ID=43127828

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20090164A CU23740A1 (es) 2009-09-29 2009-09-29 Método de obtención de una formulación de antígenos del virus de la hepatitis b

Country Status (12)

Country Link
US (1) US20120308615A1 (es)
EP (1) EP2484343A1 (es)
JP (1) JP2013505971A (es)
KR (1) KR20120080598A (es)
CN (1) CN102665687A (es)
AU (1) AU2010302740A1 (es)
BR (1) BR112012007180A2 (es)
CA (1) CA2775794A1 (es)
CU (1) CU23740A1 (es)
RU (1) RU2012117233A (es)
WO (1) WO2011038701A1 (es)
ZA (1) ZA201202768B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104043120B (zh) 2013-03-13 2017-05-31 南京赛威信生物医药有限公司 乙型肝炎疫苗
WO2017167317A1 (es) 2016-03-31 2017-10-05 Centro De Ingenieria Genetica Y Biotecnologia Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b
CN111450245A (zh) * 2020-04-29 2020-07-28 艾棣维欣(苏州)生物制药有限公司 一种乙型肝炎治疗疫苗及其制备方法
WO2025140549A1 (en) * 2023-12-29 2025-07-03 Etinpro (Beijing) Co. Ltd. Immune stimulating anti-hbsag antibody conjugates, pharmaceutical compositions, and therapeutic applications

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22290A1 (es) 1990-10-08 1995-01-31 Cigb Procedimiento para la obtencion de antigeno de superficie del virus de la hepatitis b de superior capacidad inmunoganica y su uso en un preparado vacunal
US6607727B1 (en) * 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
US20010053365A1 (en) * 1995-04-25 2001-12-20 Smithkline Beecham Biologicals S.A. Vaccines
ATE229810T1 (de) * 1996-10-11 2003-01-15 Univ California Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen
CU23002A1 (es) * 2000-12-01 2004-11-18 Ct Ingenieria Genetica Biotech Método de obtención de agregados antigénicos y su uso en formulaciones
CU23405A1 (es) * 2003-10-20 2009-08-04 Ct Ingenieria Genetica Biotech Composiciones farmacéuticas para uso terapéutico
CN1919341B (zh) * 2005-08-24 2012-01-25 复旦大学 乙肝表面抗原-抗体复合物在制备对乙肝疫苗无应答或低应答预防制品中的用途
CN1981866B (zh) * 2006-04-30 2011-04-06 解放军三○二医院生物治疗研究中心 新型慢性乙肝治疗性dc疫苗
AR065504A1 (es) * 2007-02-28 2009-06-10 Ct Ingenieria Genetica Biotech Terapia combinada para el tratamiento de la hepatitis b cronica. uso.
WO2009143524A2 (en) * 2008-05-23 2009-11-26 The Regents Of The University Of Michigan Nanoemulsion vaccines

Also Published As

Publication number Publication date
EP2484343A1 (en) 2012-08-08
JP2013505971A (ja) 2013-02-21
US20120308615A1 (en) 2012-12-06
AU2010302740A1 (en) 2012-05-24
BR112012007180A2 (pt) 2016-03-29
CN102665687A (zh) 2012-09-12
WO2011038701A1 (es) 2011-04-07
RU2012117233A (ru) 2013-11-10
ZA201202768B (en) 2012-12-27
CA2775794A1 (en) 2011-04-07
KR20120080598A (ko) 2012-07-17

Similar Documents

Publication Publication Date Title
AR087380A1 (es) Vacunas de celulas dendriticas (cd) para la terapia del cancer de pancreas
NZ592977A (en) IgE CH3 PEPTIDE VACCINE
CO2019000069A2 (es) Agentes antivirales contra la hepatitis b
MX2020003995A (es) Nuevas moleculas de acido nucleico artificiales.
PE20171648A1 (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la capsida del vhb
PE20160686A1 (es) Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infeccion por virus de la hepatitis b
CO6571891A2 (es) Inhibidores del virus de la hepatitis c.
MX2018010805A (es) Agentes antivirales contra la hepatitis b.
UY37997A (es) Agentes antivirales contra la hepatitis b
CU23740A1 (es) Método de obtención de una formulación de antígenos del virus de la hepatitis b
MX2021005850A (es) Heterociclos funcionalizados como agentes antivirales.
PE20121526A1 (es) Compuestos policiclicos heterociclicos como inhibidores del virus de la hepatitis c
ECSP14005678A (es) Composiciones y métodos para tratar el virus de la hepatitis c
AR073359A1 (es) Composiciones nutricionales con globulos lipidicos recubiertos
MX386981B (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll 7 (tlr7).
CO6592102A2 (es) Compuestos de sililo triciclicos fusionados y metodos de uso de los mismos para el tratamiento de enfermedades virales
WO2015061294A8 (en) Use of sting agonists to treat chronic hepatitis b virus infection
EA201270173A1 (ru) Получение полиовируса с высокими титрами для получения вакцины
RU2015117251A (ru) Новые соединения
UY37861A (es) Agentes antivirales contra la hepatitis b
MX2012007706A (es) Estabilizacion de peliculas de oxido de zinc en composiciones orales.
CO6321162A2 (es) Una vacuna que comprende una cantidad inmunogenica de un antigeno en somastatina y un adyuvante
MX387420B (es) Producción de virus en cultivos celulares.
PE20151086A1 (es) COMPUESTOS DERIVADOS DE 5H-PIRROLO-[3,2-d]PIRIMIDIN-4-AMINA 2,6,7 TRISUSTITUIDOS O 2,7 DISUSTITUIDOS COMO INDUCTORES DEL INTERFERON HUMANO
AR077225A1 (es) Formulaciones inyectables que contienen asenapina y metodo de tratamiento que las utiliza

Legal Events

Date Code Title Description
FG Grant of patent
FD Lapse (for not paying fees)